Global Metabolic Liver Disease Cases Projected to Reach 1.8 Billion by 2050

A significant global study, recently published in *The Lancet Gastroenterology & Hepatology*, projects that Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – previously known as Non-Alcoholic Fatty Liver Disease (NAFLD) – is set to affect 1.8 billion people worldwide by the year 2050. This represents a staggering increase, with current estimates showing 1.3 billion people globally living with MASLD in 2023, marking a 143% rise in just three decades since 1990. The findings, derived from the comprehensive Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, underscore MASLD as one of the most prevalent and rapidly escalating liver conditions across the globe. The primary drivers behind this projected surge include global population growth, alongside significant shifts in lifestyle, such as increasing rates of obesity and elevated blood sugar levels. Other contributing factors involve urbanization, sedentary habits, and poor dietary patterns. MASLD is an umbrella term encompassing liver conditions characterized by excess fat accumulation in the liver (more than 5% of liver weight) in the presence of one or more cardiometabolic risk factors – including high blood sugar, elevated body mass index (BMI), and hypertension – but independent of significant alcohol intake. The disease spectrum ranges from simple steatosis (fatty liver) to metabolic dysfunction-associated steatohepatitis (MASH), which involves inflammation and liver cell damage, potentially progressing to fibrosis, cirrhosis, and even hepatocellular carcinoma (liver cancer). The global prevalence rate of MASLD grew to 14,429 cases per 100,000 people in 2023, a 29% increase from 1990. While MASLD is generally more common in men than women and shows the highest prevalence rates in older adults (aged 80-84), a concerning trend highlights that the largest number of affected individuals are younger, typically around ages 35-39 in men and 55-59 in women. High blood sugar is identified as the leading global driver of MASLD-related health problems, followed by high BMI and smoking, emphasizing its strong links to type 2 diabetes and obesity. The study's implications for countries like India are particularly critical. The original article from 'The Indian Practitioner' highlights that in India, nearly 40% of the population faces liver issues, often without alcohol consumption, due to modern lifestyles, poor diets, and environmental factors affecting liver health across all age groups. Other sources corroborate this, indicating a sharp rise in MASLD prevalence in India, with an increase of 23.19% from 1990 to 2023. India faces a significant burden of MASLD, impacting approximately 16%-32% (around 120 million) of its population. Notably, Indians are prone to developing MASLD at lower body mass indices due to higher visceral fat accumulation and increased insulin resistance, highlighting unique regional metabolic predispositions. The rise in urban living and dietary changes in India further contribute to this growing prevalence, affecting even individuals not considered overweight. Experts stress the silent nature of MASLD as one of its most dangerous aspects, as many individuals remain unaware of their condition in the early stages due to a lack of discernible symptoms. This makes early detection and intervention paramount to prevent disease progression to more severe, irreversible liver damage. The American Association for the Study of Liver Diseases (AASLD) has launched a national initiative to improve early detection of liver fibrosis in at-risk populations, emphasizing the need for systematic screening strategies integrated across healthcare settings. Management of MASLD primarily revolves around lifestyle modifications. Even a modest reduction of 7-10% of body weight, achieved through a healthy diet rich in whole foods, fruits, vegetables, and lean proteins, coupled with regular physical activity, can significantly reduce liver fat and improve liver function. Reducing the intake of processed foods, sugary beverages, and unhealthy fats is crucial. Pharmacological treatments are also emerging, with new advancements like resmetirom (Rezdiffra) receiving FDA approval for MASH, marking a significant step in addressing the disease. The escalating global burden of MASLD presents substantial health and economic challenges worldwide, demanding urgent global health prioritization. Policymakers, healthcare systems, and public health campaigns must collaborate to raise awareness, implement preventive strategies, and enhance screening and treatment accessibility to mitigate the growing impact and prevent future complications of this silent epidemic.

Frequently Asked Questions

Read Full Story on Quick Digest